GRDN · Insider Trading
Guardian Pharmacy Services, Inc.
Every open-market purchase and sale reported by GRDN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | Jeffrey Tuch | See Remarks | M | +55,578 | — |
| 2026-09-28 | Chris Crisafulli | See Remarks | M | +18,931 | — |
| 2026-09-28 | Fred Burke | See Remarks | M | +1,298,825 | — |
| 2026-09-28 | David Norman Martin | See Remarks | M | +39,865 | — |
| 2026-09-28 | John Ackerman | Director | M | +1,884,996 | — |
| 2026-09-28 | Richard Eakins | Senior Vice President, Sales | M | +36,052 | — |
| 2026-09-28 | Robert Weir | See Remarks | M | +23,450 | — |
| 2026-09-28 | Kendall Forbes | — | M | +608,570 | — |
| 2026-09-28 | Thomas J Salentine Jr | Director | M | +6,100,175 | — |
| 2026-09-28 | Cardinal Equity Fund, L.P. | — | M | +471,057 | — |
| 2026-09-28 | William Franklin Mudd | See Remarks | M | +38,282 | — |
| 2026-09-28 | Pharmacy Investors, LLC | — | M | +1,413,939 | — |
| 2026-09-28 | David K Morris | See Remarks | M | +641,870 | — |
| 2026-09-28 | Bindley Capital Partners I, LLC | 10%+ Owner | M | +6,100,175 | — |
| 2026-09-28 | Douglas Towns | See Remarks | M | +23,450 | — |
| 2026-09-28 | William E Bindley | Director | M | +6,100,175 | — |
| 2026-05-07 | Randall J Lewis | Director | A | +4,028 | — |
| 2026-05-07 | Mary Sue Patchett | Director | A | +4,028 | — |
| 2026-05-07 | Steven D Cosler | Director | A | +4,028 | — |
| 2026-03-24 | David K Morris | See Remarks | Sell | −187,855 | −$5.58M |
| 2026-03-24 | Fred Burke | See Remarks | Sell | −671,432 | −$19.93M |
| 2026-03-24 | William E Bindley | Director | Sell | −3,570,677 | −$105.99M |
| 2026-03-24 | Pharmacy Investors, LLC | — | Sell | −827,636 | −$24.57M |
| 2026-03-24 | Kendall Forbes | See Remarks | Sell | −346,672 | −$10.29M |
| 2026-03-24 | Thomas J Salentine Jr | Director | Sell | −3,570,677 | −$105.99M |
| 2026-03-24 | John Ackerman | Director | Sell | −1,103,364 | −$32.75M |
| 2026-03-24 | Cardinal Equity Fund, L.P. | — | Sell | −275,728 | −$8.18M |
| 2026-03-24 | Bindley Capital Partners I, LLC | 10%+ Owner | Sell | −3,570,677 | −$105.99M |
| 2026-03-03 | David K Morris | See Remarks | A | +8,952 | — |
| 2026-03-03 | Kendall Forbes | See Remarks | A | +8,952 | — |
| 2026-02-13 | David K Morris | See Remarks | A | +50,000 deriv. | — |
| 2026-02-13 | Kendall Forbes | See Remarks | A | +50,000 deriv. | — |
| 2026-02-13 | Fred Burke | See Remarks | A | +75,000 deriv. | — |
| 2025-12-08 | Kendall Forbes | See Remarks | G | −21,500 | — |
| 2025-12-08 | Fred Burke | See Remarks | G | −200,000 | — |
| 2025-12-05 | Steven D Cosler | Director | Buy | +3,370 | +$99.79K |
| 2025-09-30 | Kendall Forbes | See Remarks | M | +608,570 | — |
| 2025-09-30 | David K Morris | See Remarks | M | +641,869 | — |
| 2025-09-30 | Fred Burke | See Remarks | M | +1,298,826 | — |
| 2025-09-30 | Bindley Capital Partners I, LLC | 10%+ Owner | M | +6,100,176 | — |
| 2025-09-30 | Cardinal Equity Fund, L.P. | — | MIXED | +149,794 | −$6.48M |
| 2025-09-30 | Thomas J Salentine Jr | Director | M | +6,100,176 | — |
| 2025-09-30 | William E Bindley | Director | M | +6,100,176 | — |
| 2025-09-30 | John Ackerman | Director | M | +1,884,997 | — |
| 2025-09-30 | Pharmacy Investors, LLC | — | MIXED | +449,624 | −$19.44M |
| 2025-05-29 | William E Bindley | Director | Sell | −4,160,359 | −$83.87M |
| 2025-05-29 | David K Morris | See Remarks | Sell | −437,759 | −$8.83M |
| 2025-05-29 | Fred Burke | See Remarks | Sell | −885,807 | −$17.86M |
| 2025-05-29 | Thomas J Salentine Jr | Director | Sell | −4,160,359 | −$83.87M |
| 2025-05-29 | Bindley Capital Partners I, LLC | 10%+ Owner | Sell | −4,160,359 | −$83.87M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Thomas J Salentine Jr | Director | 16,705,380 | $831.30M |
| William E Bindley | Director | 16,669,666 | $829.52M |
| Bindley Capital Partners I, LLC | 10%+ Owner | 16,669,666 | $829.52M |
| John Ackerman | Director | 3,863,806 | $192.27M |
| Pharmacy Investors, LLC | — | 3,863,806 | $192.27M |
| Fred Burke | See Remarks | 3,438,064 | $171.09M |
| Kendall Forbes | See Remarks | 1,651,059 | $82.16M |
| Cardinal Equity Fund, L.P. | — | 1,287,237 | $64.06M |
| David K Morris | See Remarks | 896,341 | $44.60M |
| Jeffrey Tuch | See Remarks | 231,847 | $11.54M |
| David Norman Martin | See Remarks | 140,905 | $7.01M |
| William Franklin Mudd | See Remarks | 136,747 | $6.80M |
| Richard Eakins | Senior Vice President, Sales | 134,930 | $6.71M |
| Douglas Towns | See Remarks | 113,006 | $5.62M |
| Robert Weir | See Remarks | 103,333 | $5.14M |
| Chris Crisafulli | See Remarks | 53,057 | $2.64M |
| Steven D Cosler | Director | 29,012 | $1.44M |
| Mary Sue Patchett | Director | 15,071 | $749.97K |
| Randall J Lewis | Director | 15,071 | $749.97K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GRDN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.